Developer docs
API playgroundTry for free, no card

Search company profiles

Enorama Pharma

Full company profile

uuid000kdnv

Namestring
Enorama Pharma
Legal namestring
Enorama Pharma AB
Websiteurl
enorama.se
Company typeenum
Public
Founded yearint
2014
Descriptiontext

Enorama Pharma AB is a Swedish pharmaceutical company listed on Nasdaq First North Growth Market (ticker sto:ERMA), headquartered in Stockholm with operational presence in Malmö. The company develops and commercializes consumer-friendly oral nicotine products across three lines: NIC-S, a 100% tobacco-free nicotine pouch brand sold in six flavors and three strengths; a patented nicotine chewing gum for smoking cessation; and ChewMed®, a proprietary platform for manufacturing medical chewing gums using a method the company describes as better suited than traditional techniques for pharmaceutical applications. The European Patent Office granted Enorama's patent on nicotine-containing chewing gum composition and manufacturing method in May 2024.

The company's go-to-market blends direct-to-consumer and B2B channels. NIC-S was launched in the US market in April 2025 and is distributed through 700+ convenience and retail stores across 21 states and an owned US e-commerce storefront, supported by earned media in Convenience Store News and trade-fair exposure at World Tobacco Middle East. On the B2B side, Enorama manufactures private-label nicotine and oral-care products for retailers and operates ChewMed® as a contract-manufacturing platform for medical chewing gum applications. Manufacturing relies on the company's modern chewing gum production technology, while R&D focus is on consumer-adapted nicotine formulations targeting the smoking cessation and tobacco harm-reduction segments.

Enorama's financial position is acute. As of March 2026, parent equity stood at SEK -25,559,465 — less than half of registered share capital of approximately SEK 11.65 million — following an FDA Refuse-to-File decision on the US subsidiary's tobacco product applications. The company has survived 2026 on related-party loans from its largest shareholder, DS Global Pte Limited (~29.81% owner), totaling USD 2 million in November 2025 plus a USD 4 million loan facility in February 2026 at 9% interest with conversion rights. An extraordinary general meeting on April 7, 2026 resolved to continue operations rather than liquidate, with the board committed to restoring equity within eight months. Bengt Jönsson serves as acting CEO.

Short descriptiontext

Enorama Pharma AB is a Swedish Nasdaq First North–listed pharmaceutical company that develops and sells the NIC-S tobacco-free nicotine pouch brand, a patented nicotine chewing gum for smoking cessation, and the ChewMed® medical chewing gum manufacturing platform, primarily serving US retail and direct-to-consumer nicotine users.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMalmö, Sweden
HQ citystring
Malmö
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
nicotine replacement therapy, nicotine pouches, pharmaceutical chewing gum, smoking cessation products, private label manufacturing
Industry4 codes
PRIMARYCRADAJAI
Nicotine Pouches (Tobacco-Free) Manufacturing & Brands
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Tobacco & Nicotine Products Manufacturing & Brands
SECONDARYCRANADAD
Nicotine Pouch Retail
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Tobacco & Nicotine Retail (Cigarettes, Cigars, Smokeless)
SECONDARYCRADAMAI
Smoking Cessation & Nicotine Replacement Therapy (Gum, Patches, Lozenges)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)
SECONDARYCRADAJAJ
Nicotine Replacement Therapy (NRT) Consumer Products Manufacturing & Brands
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Tobacco & Nicotine Products Manufacturing & Brands
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Tobacco, Electronic Cigarette, and Other Smoking Supplies Retailers459991
  • Tobacco Product and Electronic Cigarette Merchant Wholesalers42494
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Tobacco Products2100
Product category
Smoking Cessation Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Product Sales - NIC-S Brand
TypeOne Time License
Description

Sale of 100% tobacco-free nicotine pouches under the company's own NIC-S brand in 6 flavors and 3 strengths.

enorama.se
2Private Label Products
TypeOne Time License
Description

Development and commercialization of premium products under Private Label arrangements in commercially strong business areas.

enorama.se
3ChewMed Medical Chewing Gum
TypeOne Time License
Description

Manufacturing and sale of medical chewing gums developed with the company's unique technology platform.

enorama.se
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Supply Chain, Personnel, Marketing or Sales, Technology or R&D
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1NIC-S
Description

100% tobacco-free nicotine pouches available in 6 flavors and 3 strengths, marketed under own brand

enorama.se
+1 more record
Core offering1 text field

Enorama Pharma manufactures and commercializes nicotine replacement therapy products, including NIC-S nicotine pouches and Nikotintuggummi (nicotine chewing gum) sold to consumers through retail and online channels. The company also operates a proprietary ChewMed platform that enables the production of medical chewing gum for pharmaceutical ingredients, offered to business clients under private-label and licensing arrangements.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • NIC-S available in 700+ US stores across 21 states and online
Product overview1 text field

Enorama Pharma is a Swedish pharmaceutical company listed on Nasdaq First North Growth Market, focusing on the development and commercialization of consumer-friendly oral nicotine products. The portfolio consists of three main offerings: NIC-S (100% tobacco-free nicotine pouches in 6 flavors and 3 strengths), proprietary patented nicotine gum for smoking cessation, and ChewMed® for medical applications using a modern chewing gum technology platform.

Product and service3 records
1NIC-S
CategorySmoking Cessation Products
2Nikotintuggummi
CategorySmoking Cessation Products
3ChewMed
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Swedish-based online retailer of nicotine pouches and other smoke-free products. Directly comparable business model combining private label and branded nicotine pouch distribution; significant overlap in European online channels.

TypeDirect peer
Description

Altria markets On! and Helix nicotine pouch brands in the US, directly competing with NIC-S in convenience and tobacco retail channels. Comparable product (tobacco-free pouches), target consumer, and distribution model.

TypeBroad incumbent
Description

Perrigo manufactures private label and store-brand nicotine replacement therapy gum, directly comparable to Enorama's private label NRT offerings. Both target the value-tier of smoking cessation.

TypeDirect peer
Description

Philip Morris International owns Zyn, the global market-leading tobacco-free nicotine pouch brand. Directly competes with Enorama's NIC-S in the same product category, same smoke-free oral nicotine format, and overlapping retail channels in the US and Europe.

TypeDirect peer
Description

JT International's Nordic Spirit competes directly with NIC-S in the European and US nicotine pouch market with similar tobacco-free formulations. Comparable product positioning targeting smoke-free adult consumers.

TypeBroad incumbent
Description

Swedish Match (now part of Philip Morris) historically dominated Swedish-style smokeless tobacco and now leads in pouches. Comparable in heritage, geographic origin, and product category, though at vastly larger scale.

7Johnson & Johnson (Nicorette)
TypeBroad incumbent
Description

Johnson & Johnson's Nicorette is the global market-leading NRT gum brand, directly competing with Enorama's nicotine chewing gum in smoking cessation category across pharmacy and retail.

TypeBroad incumbent
Description

Haleon owns Nicotinell, a leading OTC nicotine replacement therapy gum brand. Direct competitor in Enorama's nicotine gum business, with broader portfolio and pharmacy distribution muscle.

TypeDirect peer
Description

BAT's Velo (formerly Lyft) is a major nicotine pouch brand competing in the same product category as NIC-S across US and European retail. Comparable product format, flavors, strengths, and consumer segments.

TypeEmerging player
Description

Niconovum develops OTC nicotine replacement therapy products including mouth sprays and pouches, with overlapping target use cases in smoking cessation. Comparable smaller-scale NRT innovator with similar focus on alternative delivery formats.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Enorama Pharma

Smoking Cessation Pharmaceuticalsenorama.se

Enorama Pharma AB is a Swedish Nasdaq First North–listed pharmaceutical company that develops and sells the NIC-S tobacco-free nicotine pouch brand, a patented nicotine chewing gum for smoking cessation, and the ChewMed® medical chewing gum manufacturing platform, primarily serving US retail and direct-to-consumer nicotine users.

What Enorama Pharma does

Enorama Pharma AB is a Swedish pharmaceutical company listed on Nasdaq First North Growth Market (ticker sto:ERMA), headquartered in Stockholm with operational presence in Malmö. The company develops and commercializes consumer-friendly oral nicotine products across three lines: NIC-S, a 100% tobacco-free nicotine pouch brand sold in six flavors and three strengths; a patented nicotine chewing gum for smoking cessation; and ChewMed®, a proprietary platform for manufacturing medical chewing gums using a method the company describes as better suited than traditional techniques for pharmaceutical applications. The European Patent Office granted Enorama's patent on nicotine-containing chewing gum composition and manufacturing method in May 2024.

The company's go-to-market blends direct-to-consumer and B2B channels. NIC-S was launched in the US market in April 2025 and is distributed through 700+ convenience and retail stores across 21 states and an owned US e-commerce storefront, supported by earned media in Convenience Store News and trade-fair exposure at World Tobacco Middle East. On the B2B side, Enorama manufactures private-label nicotine and oral-care products for retailers and operates ChewMed® as a contract-manufacturing platform for medical chewing gum applications. Manufacturing relies on the company's modern chewing gum production technology, while R&D focus is on consumer-adapted nicotine formulations targeting the smoking cessation and tobacco harm-reduction segments.

Enorama's financial position is acute. As of March 2026, parent equity stood at SEK -25,559,465 — less than half of registered share capital of approximately SEK 11.65 million — following an FDA Refuse-to-File decision on the US subsidiary's tobacco product applications. The company has survived 2026 on related-party loans from its largest shareholder, DS Global Pte Limited (~29.81% owner), totaling USD 2 million in November 2025 plus a USD 4 million loan facility in February 2026 at 9% interest with conversion rights. An extraordinary general meeting on April 7, 2026 resolved to continue operations rather than liquidate, with the board committed to restoring equity within eight months. Bengt Jönsson serves as acting CEO.

Enorama Pharma firmographics

Firmographics
Name
Enorama Pharma
Legal name
Enorama Pharma AB
Website
https://enorama.se
Company type
Public
Founded year
2014
Operating status
Operating
Headcount range
1–10 employees
Short description
Enorama Pharma AB is a Swedish Nasdaq First North–listed pharmaceutical company that develops and sells the NIC-S tobacco-free nicotine pouch brand, a patented nicotine chewing gum for smoking cessation, and the ChewMed® medical chewing gum manufacturing platform, primarily serving US retail and direct-to-consumer nicotine users.
Ownership category
akta.pro rank

Enorama Pharma industry classification

Industry
Product category
Smoking Cessation Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Tobacco, Electronic Cigarette, and Other Smoking Supplies Retailers (459991), Tobacco Product and Electronic Cigarette Merchant Wholesalers (42494)
SIC
Pharmaceutical Preparations (2834), Tobacco Products (2100)
akta.pro industry
PRIMARYCRADAJAI
Nicotine Pouches (Tobacco-Free) Manufacturing & Brands
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Tobacco & Nicotine Products Manufacturing & Brands
SECONDARYCRANADAD
Nicotine Pouch Retail
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Tobacco & Nicotine Retail (Cigarettes, Cigars, Smokeless)
SECONDARYCRADAMAI
Smoking Cessation & Nicotine Replacement Therapy (Gum, Patches, Lozenges)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)
SECONDARYCRADAJAJ
Nicotine Replacement Therapy (NRT) Consumer Products Manufacturing & Brands
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Tobacco & Nicotine Products Manufacturing & Brands

Keywords

  • Nicotine replacement therapy
  • Nicotine pouches
  • Pharmaceutical chewing gum
  • Smoking cessation products
  • Private label manufacturing

Where Enorama Pharma is headquartered

Location

Headquarters

HQ city
Malmö
HQ country
Sweden
HQ region
Europe

Offices2 records

Markets served

Enorama Pharma business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Personnel, Marketing or Sales, Technology or R&D

Revenue model

  1. Product Sales - NIC-S Brand: Sale of 100% tobacco-free nicotine pouches under the company's own NIC-S brand in 6 flavors and 3 strengths.
  2. Private Label Products: Development and commercialization of premium products under Private Label arrangements in commercially strong business areas.
  3. ChewMed Medical Chewing Gum: Manufacturing and sale of medical chewing gums developed with the company's unique technology platform.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Enorama Pharma product offering

Product offering

Core offering

Enorama Pharma manufactures and commercializes nicotine replacement therapy products, including NIC-S nicotine pouches and Nikotintuggummi (nicotine chewing gum) sold to consumers through retail and online channels. The company also operates a proprietary ChewMed platform that enables the production of medical chewing gum for pharmaceutical ingredients, offered to business clients under private-label and licensing arrangements.

Product overview

Enorama Pharma is a Swedish pharmaceutical company listed on Nasdaq First North Growth Market, focusing on the development and commercialization of consumer-friendly oral nicotine products. The portfolio consists of three main offerings: NIC-S (100% tobacco-free nicotine pouches in 6 flavors and 3 strengths), proprietary patented nicotine gum for smoking cessation, and ChewMed® for medical applications using a modern chewing gum technology platform.

Differentiator

Problem solved

Functional benefit

Brands

  • NIC-S: 100% tobacco-free nicotine pouches available in 6 flavors and 3 strengths, marketed under own brand
  • ChewMed

Products and services

  • NIC-S
  • Nikotintuggummi
  • ChewMed

Quantifiable outcome

  • NIC-S available in 700+ US stores across 21 states and online

Companies that use Enorama Pharma

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Enorama Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Enorama Pharma partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Enorama Pharma competitors and assessment

Company assessment

Direct peers

  • Haypp Group: Swedish-based online retailer of nicotine pouches and other smoke-free products. Directly comparable business model combining private label and branded nicotine pouch distribution; significant overlap in European online channels.
  • Altria Group (On! / Helix): Altria markets On! and Helix nicotine pouch brands in the US, directly competing with NIC-S in convenience and tobacco retail channels. Comparable product (tobacco-free pouches), target consumer, and distribution model.
  • Philip Morris International (Zyn): Philip Morris International owns Zyn, the global market-leading tobacco-free nicotine pouch brand. Directly competes with Enorama's NIC-S in the same product category, same smoke-free oral nicotine format, and overlapping retail channels in the US and Europe.
  • Japan Tobacco International (Nordic Spirit): JT International's Nordic Spirit competes directly with NIC-S in the European and US nicotine pouch market with similar tobacco-free formulations. Comparable product positioning targeting smoke-free adult consumers.
  • British American Tobacco (Velo): BAT's Velo (formerly Lyft) is a major nicotine pouch brand competing in the same product category as NIC-S across US and European retail. Comparable product format, flavors, strengths, and consumer segments.

Broad incumbents

  • Perrigo Company: Perrigo manufactures private label and store-brand nicotine replacement therapy gum, directly comparable to Enorama's private label NRT offerings. Both target the value-tier of smoking cessation.
  • Swedish Match (legacy snus portfolio): Swedish Match (now part of Philip Morris) historically dominated Swedish-style smokeless tobacco and now leads in pouches. Comparable in heritage, geographic origin, and product category, though at vastly larger scale.
  • Johnson & Johnson (Nicorette): Johnson & Johnson's Nicorette is the global market-leading NRT gum brand, directly competing with Enorama's nicotine chewing gum in smoking cessation category across pharmacy and retail.
  • Haleon (Nicotinell): Haleon owns Nicotinell, a leading OTC nicotine replacement therapy gum brand. Direct competitor in Enorama's nicotine gum business, with broader portfolio and pharmacy distribution muscle.

Emerging players

  • Niconovum: Niconovum develops OTC nicotine replacement therapy products including mouth sprays and pouches, with overlapping target use cases in smoking cessation. Comparable smaller-scale NRT innovator with similar focus on alternative delivery formats.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Enorama Pharma social profiles

Digital presence

Enorama Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Enorama Pharma leadership team

Management profile

Number of profiles

Profiles8 records

Enorama Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Enorama Pharma funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Enorama Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Enorama Pharma

What does Enorama Pharma do?

Enorama Pharma manufactures and commercializes nicotine replacement therapy products, including NIC-S nicotine pouches and Nikotintuggummi (nicotine chewing gum) sold to consumers through retail and online channels. The company also operates a proprietary ChewMed platform that enables the production of medical chewing gum for pharmaceutical ingredients, offered to business clients under private-label and licensing arrangements.

Is Enorama Pharma a public or private company?

Enorama Pharma is a public company. It is classified as public and is currently operating.

When was Enorama Pharma founded?

Enorama Pharma was founded in 2014. It employs 1 to 10 people.

Where is Enorama Pharma based?

Enorama Pharma is headquartered in Malmö, Sweden, in the Europe region.

How does Enorama Pharma make money?

Three revenue lines are on record. Product Sales - NIC-S Brand is the primary driver. The others are private Label Products and chewMed Medical Chewing Gum.

Who are Enorama Pharma's main competitors?

Direct peers on record are Haypp Group, Altria Group (On! / Helix), Philip Morris International (Zyn), Japan Tobacco International (Nordic Spirit) and British American Tobacco (Velo). Broad incumbents are Perrigo Company, Swedish Match (legacy snus portfolio), Johnson & Johnson (Nicorette) and Haleon (Nicotinell). Niconovum is listed as an emerging player.

Does Enorama Pharma have an API?

No public API is recorded for Enorama Pharma.

What industry is Enorama Pharma in?

Enorama Pharma's product category is Smoking Cessation Pharmaceuticals. Its primary akta.pro industry code is CRADAJAI, Nicotine Pouches (Tobacco-Free) Manufacturing & Brands, with a secondary code of CRANADAD, Nicotine Pouch Retail. Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
news.cision.comNotice of extraordinary general meeting and second meeting for liquidation purposes in Enorama Pharma AB (publ)Enorama Pharma AB will hold an extraordinary general meeting on 4 December 2026 to consider a loan interest rate and whether to continue operations or liquidate. The board proposes continuing operations, with a secondary liquidation option, after a second balance sheet for liquidation purposes is presented.news.cision.comEnorama Pharma AB (publ) postpones publication of its interim report for the third quarter of 2026Enorama Pharma AB's board postponed the publication of its Q3 2026 interim report from 18 November to 27 November 2026. The delay is for administrative reasons. The company, listed on Nasdaq First North Growth Market, is a producer of oral nicotine products.Dagens industriNollomsättning för tuggummibolagetEnorama Pharma reported a operating loss of 11.7 million SEK for the second quarter of 2026, an improvement from the 15.3 million SEK loss in the same period last year. The company manufactures medical chewing gum and released these financial results on August 19, 2026.news.cision.comEnorama Pharma: PRESS RELEASE FROM THE EXTRAORDINARY GENERAL MEETING, AND FIRST CONTROL MEETING, IN ENORAMA PHARMA AB (PUBL)Enorama Pharma AB held an extraordinary general meeting on April 7, 2026, where shareholders resolved to continue the company's operations and avoid liquidation. The board of directors expects to restore the company's equity within eight months through capital injection and capital raising measures from existing and new investors, in compliance with the Swedish Companies Act. A second control meeting will be convened within eight months to reconsider liquidation if the required capital has not been restored by that time.news.cision.comNotice of extraordinary general meeting and first control meeting in Enorama Pharma AB (publ)Enorama Pharma AB has convened an extraordinary general meeting on April 7, 2026 to address a critical financial situation where the company's equity stands at SEK -25,559,465, less than half of its registered share capital of approximately SEK 11.65 million. The crisis stems from the company's US subsidiary Enorama Pharma Inc. receiving a Refuse-to-File decision from the FDA regarding tobacco product applications, triggering an asset revaluation. The board is proposing two resolutions: primarily to continue operations with capital injection measures from existing shareholders and new investors, including a USD 4 million loan from main shareholder DS Global Pte Limited; and secondarily, liquidation, with estimated shareholder distributions of SEK 0 per share.news.cision.comNotice of extraordinary general meeting in Enorama Pharma AB (publ)Enorama Pharma AB has called an extraordinary general meeting for 11 March 2026 to seek shareholder approval for two related party loan transactions with DS Global Pte. Limited, its largest shareholder holding approximately 29.81 percent of shares. The first proposal involves extending an existing loan of approximately SEK 5.2 million from 28 February 2026 to 31 December 2027 at 10 percent annual interest. The second proposal approves a new USD 4 million loan facility at 9 percent annual interest, with DS Global granted the right to convert outstanding amounts into Enorama Pharma shares at a 10 percent discount to the volume-weighted average price at maturity.MarketScreenerEnorama Pharma AB Enters into Loan Agreement with Ds Global Pte LimitedEnorama Pharma AB entered into a loan agreement with its major shareholder DS Global Pte Limited on November 7, 2025, which was approved by the general meeting. The agreement involves a USD two million loan facility from DS Global to Enorama Pharma. Further details were disclosed in the company's notice of the extraordinary general meeting and the board of directors report.EnoramaKOMMUNIKÉ FRÅN EXTRA BOLAGSSTÄMMA I ENORAMA PHARMA AB (PUBL)Enorama Pharma AB held an extraordinary shareholders' meeting on December 2, 2025, which approved a related-party loan agreement with its major shareholder DS Global Pte Limited. The approved loan facility amounts to USD 2,000,000 and was originally entered into on November 7, 2025, conditional upon shareholder ratification. Shares held by DS Global were excluded from the voting on this decision.NasdaqBULLETIN FROM THE EXTRAORDINARY GENERAL MEETING IN ENORAMA PHARMA AB (PUBL)Enorama Pharma AB's extraordinary general meeting held on December 2, 2025 approved a related party loan agreement with major shareholder DS Global Pte Limited, providing the company with a USD 2 million loan facility originally entered into on November 7, 2025. The resolution was passed with DS Global excluded from the vote due to its conflict of interest as the counterparty to the transaction. This funding through a shareholder loan represents a routine corporate financing mechanism for the Nasdaq First North Growth Market-listed company.news.cision.comBULLETIN FROM THE EXTRAORDINARY GENERAL MEETING IN ENORAMA PHARMA AB (PUBL)An extraordinary general meeting was held in Enorama Pharma AB on 2 December 2025, resolving to approve a loan agreement with major shareholder DS Global Pte Limited. Under the agreement, DS Global provides a USD 2,000,000 loan facility to Enorama Pharma, with the transaction having been entered into on 7 November 2025 subject to shareholder approval. Shares held directly or indirectly by DS Global were excluded from the voting calculation on this related party transaction.